Thrombocytopenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
Progression‐free survival · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in progression‐free survival ‐ first‐line studies compared with placebo or standard of care (low certainty).
1 finding from 1 review
Progression‐free survival ‐ recurrent disease studies · glioblastoma in adults
Anti‐EGFR therapy may leads to lower progression‐free survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).
1 finding from 1 review
Overall survival (5‐year) · women (18 years and older) diagnosed with stage IB2 cervical cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Progression‐free survival (PSF) · women (18 years and older) diagnosed with stage IB2 cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · women (18 years and older) diagnosed with stage IB2 cervical cancer
It is very uncertain whether chemoradiotherapy changes recurrence compared with radical surgery (very low certainty).
1 finding from 1 review
Adverse events: lymphoedema · women (18 years and older) diagnosed with stage IB2 cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (flu‐like symptoms) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (fatigue) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Neurotoxicity · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (neurotoxicity) compared with chemotherapy alone (low certainty).
1 finding from 1 review
The incidence and severity of chemotherapy‐ or radiotherapy‐related toxicities · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival · high‐grade glioma
It is very uncertain whether hypofractionated radiotherapy changes overall survival compared with daily conventionally fractionated radiotherapy (very low certainty).
1 finding from 1 review